12 January 2017

A paper by Ellen van Agtmaal from the group of Rick Wansink and Bé Wieringa, Dept. of Cell Biology hit the cover of the January issue of Molecular Therapy (Cell Press) with a gene editing strategy for myotonic dystrophy.

Myotonic dystrophy (DM) is the most frequent inherited neuromuscular degenerative disorder in adults, which manifests itself at different ages with variable expression of progressive skeletal muscle wasting, myotonia, heart and gastrointestinal problems, insulin resistance, cataract and alterations in cognitive functions and behavior. DM’s multisystemic symptoms are caused by expansion of an unstable (CTG•CAG)n triplet repeat in the DMPK gene and the overlapping DM1-antisense gene.

The Nijmegen group, in collaboration with colleagues from Paris and Glasgow, explored a DNA-directed therapeutic strategy for treatment of DM. They demonstrate that excision of the triplet repeat from an expanded DMPK allele in myoblasts from DM patients or a DM mouse model can be achieved at high frequency by dual CRISPR/Cas9-cleavage at either side of the repeat sequence. Unexpectedly, single cleavage in either its 5’ or 3’ flank promotes uncontrollable deletion of large segments from the expanded repeat, rather than formation of short indels usually seen after double-strand break repair. Precise removal of the repeat corrected myogenic capacity of patient muscle cells as well as the abnormal nucleocytoplasmic distribution and protein binding behavior of mutant DMPK transcripts. Dual CRISPR/Cas9-guided excision of the (CTG•CAG)n tract is thus applicable for the development of isogenic corrected DM cell lines for fundamental research and will also provide new opportunities for somatic gene therapy for patients with DM.

Ellen van Agtmaal (first author) and Rick Wansink and Bé Wieringa (senior authors) published their findings in Molecular Therapy.
 

Related news items


Rubicon grants awarded to three RIMLS researchers

19 April 2022 Three researchers have received Rubicon funding from NWO/ZonMw. This will enable Elke Muntjewerff, Laura de Vries and Laurens van de Wiel to do research at a foreign research institute for the next two years. read more

ERC Proof of Concept Grant for Martijn Verdoes

8 March 2022 Martijn Verdoes, group leader Chemical Immunology at the department of Tumor Immunology, has been awarded an ERC Proof of Concept (PoC) Grant. The ERC PoC Grants are designed to support ERC grantees with the commercial or societal application of the results of their funded research. read more

Three VIDI grants for RIMLS researchers

24 May 2019 Matthijs Jore, Daniele Tauriello and Johannes Textor are each to receive up to 800,000 euros to develop an innovative research theme and to build up their own research group. NWO is awarding the Vidi grant as part of the Innovational Research Incentives Scheme. read more

RIMLS awards festival Twelve winners

16 January 2019 In 5 categories RIMLS young researchers received an award and bonus during the New Year's drinks. See all photo's. read more

TURBO grants for four medical-technical research projects

8 November 2018 Four TURBO grants were awarded to new technical-medical research proposals. The grants are part of the TURBO program, a collaboration between Radboudumc and the University of Twente. read more

The interplay between migrating cells and tissue mechanics

5 January 2018 Reviewed in Nature cell biology. read more